278 related articles for article (PubMed ID: 26414880)
1. Acute and chronic systemic corticosteroid-related complications in patients with severe asthma.
Lefebvre P; Duh MS; Lafeuille MH; Gozalo L; Desai U; Robitaille MN; Albers F; Yancey S; Ortega H; Forshag M; Lin X; Dalal AA
J Allergy Clin Immunol; 2015 Dec; 136(6):1488-1495. PubMed ID: 26414880
[TBL] [Abstract][Full Text] [Related]
2. Dose-Response Relationship Between Long-Term Systemic Corticosteroid Use and Related Complications in Patients with Severe Asthma.
Dalal AA; Duh MS; Gozalo L; Robitaille MN; Albers F; Yancey S; Ortega H; Forshag M; Lin X; Lefebvre P
J Manag Care Spec Pharm; 2016 Jul; 22(7):833-47. PubMed ID: 27348284
[TBL] [Abstract][Full Text] [Related]
3. Impact of omalizumab on emergency-department visits, hospitalizations, and corticosteroid use among patients with uncontrolled asthma.
Lafeuille MH; Dean J; Zhang J; Duh MS; Gorsh B; Lefebvre P
Ann Allergy Asthma Immunol; 2012 Jul; 109(1):59-64. PubMed ID: 22727159
[TBL] [Abstract][Full Text] [Related]
4. Burden of systemic glucocorticoid-related complications in severe asthma.
Lefebvre P; Duh MS; Lafeuille MH; Gozalo L; Desai U; Robitaille MN; Albers F; Yancey S; Ortega H; Forshag M; Lin X; Dalal AA
Curr Med Res Opin; 2017 Jan; 33(1):57-65. PubMed ID: 27627132
[TBL] [Abstract][Full Text] [Related]
5. Resource utilization in asthma: combined fluticasone propionate/salmeterol compared with inhaled corticosteroids.
Friedman HS; Yawn BP
Curr Med Res Opin; 2007 Feb; 23(2):427-34. PubMed ID: 17288696
[TBL] [Abstract][Full Text] [Related]
6. A comparison of budesonide/formoterol maintenance and reliever therapy versus conventional best practice in asthma management in Spain.
Quirce S; Barcina C; Plaza V; Calvo E; Muñoz M; Ampudia R; Capel M
J Asthma; 2011 Oct; 48(8):839-47. PubMed ID: 21942354
[TBL] [Abstract][Full Text] [Related]
7. Ratio of controller to total asthma medications: determinants of the measure.
Broder MS; Gutierrez B; Chang E; Meddis D; Schatz M
Am J Manag Care; 2010 Mar; 16(3):170-8. PubMed ID: 20225912
[TBL] [Abstract][Full Text] [Related]
8. The cost of systemic corticosteroid-induced morbidity in severe asthma: a health economic analysis.
Barry LE; Sweeney J; O'Neill C; Price D; Heaney LG
Respir Res; 2017 Jun; 18(1):129. PubMed ID: 28651591
[TBL] [Abstract][Full Text] [Related]
9. Association of low-dosage systemic corticosteroid use with disease burden in asthma.
Matsunaga K; Adachi M; Nagase H; Okoba T; Hayashi N; Tohda Y
NPJ Prim Care Respir Med; 2020 Aug; 30(1):35. PubMed ID: 32753647
[TBL] [Abstract][Full Text] [Related]
10. Real-world association between systemic corticosteroid exposure and complications in US patients with severe asthma.
Casale TB; Corbridge T; Germain G; Laliberté F; MacKnight SD; Boudreau J; Duh MS; Deb A
Allergy Asthma Clin Immunol; 2024 Mar; 20(1):25. PubMed ID: 38532489
[TBL] [Abstract][Full Text] [Related]
11. Complications and Health Care Resource Utilization Associated with Systemic Corticosteroids in Children and Adolescents with Persistent Asthma.
Sullivan PW; Ghushchyan VH; Skoner DP; LeCocq J; Park S; Zeiger RS
J Allergy Clin Immunol Pract; 2021 Apr; 9(4):1541-1551.e9. PubMed ID: 33290914
[TBL] [Abstract][Full Text] [Related]
12. Systemic Corticosteroid-related Adverse Outcomes and Health Care Resource Utilization and Costs Among Patients with Chronic Rhinosinusitis with Nasal Polyposis.
Davis GE; Zeiger RS; Emmanuel B; Chung Y; Tran TN; Evans KA; Chen S; Katial R; Kreindler JL; Tkacz J
Clin Ther; 2022 Sep; 44(9):1187-1202. PubMed ID: 36057475
[TBL] [Abstract][Full Text] [Related]
13. Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation.
Sullivan PW; Campbell JD; Ghushchyan VH; Globe G; Lange J; Woolley JM
J Asthma; 2015 Sep; 52(7):669-80. PubMed ID: 25731600
[TBL] [Abstract][Full Text] [Related]
14. Comparative safety and costs of stepping down asthma medications in patients with controlled asthma.
Rank MA; Liesinger JT; Branda ME; Gionfriddo MR; Schatz M; Zeiger RS; Shah ND
J Allergy Clin Immunol; 2016 May; 137(5):1373-1379.e3. PubMed ID: 26506020
[TBL] [Abstract][Full Text] [Related]
15. Healthcare resource utilization and costs associated with incremental systemic corticosteroid exposure in asthma.
Voorham J; Xu X; Price DB; Golam S; Davis J; Zhi Jie Ling J; Kerkhof M; Ow M; Tran TN
Allergy; 2019 Feb; 74(2):273-283. PubMed ID: 29987879
[TBL] [Abstract][Full Text] [Related]
16. Economic analysis of the phase III MENSA study evaluating mepolizumab for severe asthma with eosinophilic phenotype.
Basu A; Dalal A; Canonica GW; Forshag M; Yancey SW; Nagar S; Bell CF
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):121-131. PubMed ID: 28277854
[TBL] [Abstract][Full Text] [Related]
17. Evaluating direct costs and productivity losses of patients with asthma receiving GINA 4/5 therapy in the United States.
Settipane RA; Kreindler JL; Chung Y; Tkacz J
Ann Allergy Asthma Immunol; 2019 Dec; 123(6):564-572.e3. PubMed ID: 31494235
[TBL] [Abstract][Full Text] [Related]
18. [Use of resources and costs associated with non-adherence to inhaled corticosteroid treatment in asthma].
Sicras-Mainar A; Huerta A; Sánchez D; Navarro-Artieda R
Semergen; 2018; 44(1):13-22. PubMed ID: 28456499
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of risk factors and health outcomes among persons with asthma.
Smith K; Warholak T; Armstrong E; Leib M; Rehfeld R; Malone D
J Asthma; 2009 Apr; 46(3):234-7. PubMed ID: 19373629
[TBL] [Abstract][Full Text] [Related]
20. Systemic Corticosteroid-Related Complications and Costs in Adults with Persistent Asthma.
Zeiger R; Sullivan P; Chung Y; Kreindler JL; Zimmerman NM; Tkacz J
J Allergy Clin Immunol Pract; 2020; 8(10):3455-3465.e13. PubMed ID: 32679349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
